Influence of combined pathogenetic treatment on the dynamics of epicardial fat thickness in patients with cad and metabolic syndrome
Abstract
Aim. To evaluate the influence of combined hypolipidemic therapy (statins in combination with ezetimibe and fenofibrate) and sodium-glucose cotransporter 2 inhibitors on epicardial fat thickness in patients with coronary heart disease and metabolic syndrome.
Materials and methods: The study included 49 patients with coronary heart disease and metabolic syndrome who underwent treatment at the Republican Specialized Scientific and Practical Medical Center of Cardiology. The patients were divided into 2 groups: 1) intensive statin therapy in combination with ezetimibe, 2) with the addition of fenofibrate and SGLT2 inhibitors. All patients underwent biochemical tests and imaging marker assessments, followed by comparison of the dynamics within and between groups.
Results. When comparing two groups receiving different types of therapy, both groups demonstrated a significant decrease in lipid parameters: LDL-C p<0.001, TC p<0.001, TG p<0.001. Additionally, the group treated with fenofibrate and SGLT2 inhibitors showed a more significant reduction in epicardial fat (11.4 mm in the first group and 10.4 mm in the second group, p<0.05).
Conclusion: Pathogenetic therapy with the inclusion of fenofibrate and SGLT2 inhibitors more effectively reduces the level of EFT, as well as TG, VLDL-C, and the TG/HDL index.
About the Authors
List of references
Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192(31):E875-E891. https://doi.org/10.1503/cmaj.191707.
Fru¨hbeck G, Toplak H, Woodward E, Yumuk V, Maislos M, Oppert JM, et al. Obesity: the gateway to ill health – an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts. 2013;6(2):117-120. https://doi.org/10.1159/000350627.
World Health Organization. Obesity and overweight [Internet]. Geneva: WHO; 2015 [cited 2015 Nov 30]. Available from: https://www.who.int/mediacentre/factsheets/fs311/en/.
World Health Organization. World health statistics 2015 [Internet]. Geneva: WHO; 2015 [cited 2015 Nov 30]. p. 101-111. Available from: https://www.who.int/gho/publications/world_health_statistics/2015/en/.
Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008;32(9):1431-1437. https://doi.org/10.1038/ijo.2008.102.
Finer N. Medical consequences of obesity. Medicine (Abingdon). 2015;43(2):88-93. https://doi.org/10.1 016/j.mpmed.2014.11.010.
Mo¨hlig M, Boeing H, Spranger J, et al. Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. J Clin Endocrinol Metab. 2004;89(4):1885-1890. https://doi.org/10.1210/jc.2003-031101.
Kristiansen OP, Nolsøe RL, Larsen L, et al. Association of a functional 17-estradiol-sensitive IL6-174G/C promoter polymorphism with early-onset type 1 diabetes in females. Hum Mol Genet. 2003;12(10):1101- 1110. https://doi.org/10.1093/hmg/ddg132.
Kuzmina LP, Khotuleva AG. Polimorfizm gena interleykina-6 kak kriteriy riska razvitiya metabolicheskikh narusheniy u bol’nykh professional’noy bronkhial’noy astmoy [Interleukin-6 gene polymorphism as a risk factor of developing metabolic disorders in patients with occupational asthma]. Profilakticheskaya Meditsina [Preventive Medicine]. 2016;19(2):44-46. (In Russ.)
Mustafina IA, Ionin VA, Dolganov AA, Ishmetov VSh, Pushkareva AE, Yagudin TA, et al. The role of epicardial adipose tissue in the development of cardiovascular diseases. Russ J Cardiol. 2022;27(1S):4872. https://doi.org/10.15829/1560-4071-2022-4872. (In Russ.)
Forouzandeh F, Chang SM, Muhyieddeen K, et al. Does quantifying epicardial and intrathoracic fat with noncontrast computed tomography improve risk stratification beyond calcium scoring alone? Circ Cardiovasc Imaging. 2013;6(1):58-66. https://doi.org/10.1161/CIRCIMAGING.112.976316.
Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr. 2009;22(12):1311-1319. https://doi.org/10.1016/j.echo.2009.10.013.
Drapkina OM, Ivashkin VT. Abdominal pain. Ross Zh Gastroenterol Gepatol Koloproktol [Russian Journal of Gastroenterology, Hepatology, Coloproctology]. 2002;12(4):8-15. (In Russ.)
Brook RD. Obesity, weight loss, and vascular function. Endocrine. 2006;29(1):21-25. https://doi.org/10.1 385/ENDO:29:1:21.
Brook RD. Obesity, weight loss, and vascular function. Endocrine. 2006;29(1):21-25. https://doi.org/10.1 385/ENDO:29:1:21.
Tsao HM, Hu WC, Wu MH, et al. Quantitative analysis of quantity and distribution of epicardial adipose tissue surrounding the left atrium in patients with atrial fibrillation and its effect on recurrence after ablation. Am J Cardiol. 2011;107(10):1498-1503. https://doi.org/10.1016/j.amjcard.2011.01.027.
Bornachea O, Vea A, Llorente-Cortes V. Interplay between epicardial adipose tissue, metabolic and cardiovascular diseases. Clin Investig Arterioscler. 2018;30(5):230-239. https://doi.org/10.1016/j.arteri. 2018.03.003.
Braha A, Timar B, Diaconu L, Lupusoru R, Vasiluta L, Sima A, et al. Dynamics of epicardiac fat and heart function in type 2 diabetic patients initiated with SGLT-2 inhibitors. Diabetes Metab Syndr Obes. 2019;12:2559-2566. https://doi.org/10.2147/DMSO.S223629.
Do¨ nmez Y, Bulut A. Epicardial fat thickness is significantly increased and related to LDL cholesterol level in patients with familial hypercholesterolemia. J Ultrasound. 2019;22(3):309-314. https://doi.org/10.1007/s40477-019-00368-3.
Erratum in: Neurology. 2020;94(14):e1626. https://doi.org/10.1212/WNL.0000000000008362. PMID:31591276
Cinti F, Leccisotti L, Sorice GP, Capece U, D’Amario D, Lorusso M, et al. Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes. Cardiovasc Diabetol. 2023;22(1):349. https://doi.org/10.1186/s12933-023-02091-0.
Song XT, Wei YL, Rui YF, Fan L. Echocardiographic evaluation of the effect of dapagliflozin on epicardial adipose tissue and left ventricular systolic function in type 2 diabetes mellitus. J Diabetes Complications. 2023;37(7):108509. https://doi.org/10.1016/j.jdiacomp.2023.108509.
Elam MB, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017;2(4):370-380. https://doi.org/10.1001/jamacardio.20 16.4828.
Elam M, Lovato L, Ginsberg H. The ACCORD-Lipid study: implications for treatment of dyslipidemia in type 2 diabetes mellitus. Clin Lipidol. 2011;6(1):9-20. https://doi.org/10.2217/clp.10.84.
Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14(1):1-10. https://doi.org/10.1007/s11883-011-0219-7.
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): a randomised controlled trial. Lancet. 2005;366(9500):1849-1861. https://doi.org/10.1016/S0140-6736(05)67667-2.
Copyright (c) 2025 А.Р. Ким , А.Б. Шек , Р.Б. Алиева (Автор)
This work is licensed under a Creative Commons Attribution 4.0 International License.